COPENHAGEN: Weekly Results Summary Feb 21
The OMX Copenhagen 25 index rose by +0.88% this week. The earnings season highlights a contrast in the healthcare sector: while ALK-Abelló is enjoying sales success, Genmab and Zealand Pharma are making costly bets on the future. In the industrial sector, the market rewarded DFDS's restructuring plan despite a loss, while FLSmidth's strong results led to profit-taking.
ALK-BALK-Abelló (ALK-B)
ALK-Abelló reported an exceptionally strong quarter, with operating profit soaring by 89%. The result was driven by a 15% increase in allergy tablet sales and the successful launch of its new drug, neffy®. Although the departure of the head of R&D raised some questions, the company raised its 2026 revenue forecast to a range of 11–15%. The stock finished the week up 1.2%, reflecting investor satisfaction with the strategy's execution.
Create a free account to continue
Registration is free - the full analysis with all companies and the conclusion is waiting in the app.
Free account - no credit card needed
The information provided is not investment advice. RYTM analyses are generated with AI assistance and are intended for informational purposes only. Always do your own research before making investment decisions.